Journal
ONCOGENE
Volume 40, Issue 44, Pages 6258-6272Publisher
SPRINGERNATURE
DOI: 10.1038/s41388-021-02018-7
Keywords
-
Funding
- RSF [19-74-00120]
- RFBR [20-34-70119]
- Ministry of Science and Higher Education of the Russian Federation [075-15-2019-1660]
- Russian Foundation for Basic Research [19-29-01108]
- Russian Science Foundation [19-74-00120] Funding Source: Russian Science Foundation
Ask authors/readers for more resources
The study developed a survival prediction model for NB patients based on the expression of 48 growth factor-related genes, identified signaling pathways associated with treatment response in NB patients, and showed the protective effects of growth factors EPO and NGF against anti-NB multikinase inhibitors in vitro. Considering growth factor signaling activity benefits NB outcome prediction and tailoring therapy regimens for NB.
Neuroblastoma (NB) has a low frequency of recurrent mutations compared to other cancers, which hinders the development of targeted therapies and novel risk stratification strategies. Multikinase inhibitors have shown potential in treating high-risk NB, but their efficacy is likely impaired by the cancer cells' ability to adapt to these drugs through the employment of alternative signaling pathways. Based on the expression of 48 growth factor-related genes in 1189 NB tumors, we have developed a model for NB patient survival prediction. This model discriminates between stage 4 NB tumors with favorable outcomes (>80% overall survival) and very poor outcomes (<10%) independently from MYCN-amplification status. Using signaling pathway analysis and gene set enrichment methods in 60 NB patients with known therapy response, we identified signaling pathways, including EPO, NGF, and HGF, upregulated in patients with no or partial response. In a therapeutic setting, we showed that among six selected growth factors, EPO, and NGF showed the most pronounced protective effects in vitro against several promising anti-NB multikinase inhibitors: imatinib, dasatinib, crizotinib, cabozantinib, and axitinib. Mechanistically kinase inhibitors potentiated NB cells to stronger ERK activation by EPO and NGF. The protective action of these growth factors strongly correlated with ERK activation and was ERK-dependent. ERK inhibitors combined with anticancer drugs, especially with dasatinib, showed a synergistic effect on NB cell death. Consideration of growth factor signaling activity benefits NB outcome prediction and tailoring therapy regimens to treat NB.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available